Latest Regulatory News

333D Limited has responded to ASX queries, clarifying that its Bitcoin Treasury Management Policy approval is not price sensitive, while disclosing a $370,500 Bitcoin acquisition funded partly by R&D tax incentives.

oOh!media has confirmed its half-year earnings for 2025 met market expectations, despite a significant non-cash impairment linked to the loss of a key Auckland Transport contract. The company maintains steady operational performance and updated guidance amid evolving market conditions.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

IPH Limited has clarified that its FY25 underlying earnings aligned closely with market consensus, addressing ASX concerns amid a notable share price drop post-results. The company attributes the share price movement to external operational challenges rather than earnings surprises.

CZR Resources has satisfied all conditions precedent for the sale of its Robe Mesa Iron Ore Project, with completion set for 9 September 2025. This milestone marks a significant cash inflow for the company.

Advanced Braking Technology (ABT) reported robust FY25 financial results marked by revenue growth and improved profitability, while advancing its strategic roadmap focused on mining safety innovations and global market expansion.

Cauldron Energy has terminated its purchase agreement for river sand leases at Carnarvon and Derby, retaining the Onslow tenements with no further payments required, including cancellation of 2 million shares.

archTIS Limited has opened the retail component of a $17 million entitlement offer to support its acquisition of Spirion LLC’s assets, aiming to expand its US footprint and enhance its cybersecurity product suite.

PolyNovo Limited stands to benefit from proposed U.S. Medicare changes that introduce a flat reimbursement rate for outpatient wound care skin substitutes, potentially reshaping the competitive landscape in favour of cost-effective, clinically proven products.

IMEXHS Limited reported steady revenue growth and a strategic push to scale its SaaS medical imaging platform, while navigating margin challenges and regulatory risks in Colombia.

Race Oncology has activated its first clinical trial site in Hong Kong for the Phase 1 study of RC220 combined with doxorubicin in advanced solid tumours, marking a significant step in accelerating patient enrolment and broadening clinical data.

Dotz Nano has responded to an ASX price query following unusual trading activity, confirming no undisclosed information and reaffirming compliance with continuous disclosure rules.